Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) has shared an update.
Perseus Proteomics Inc. has entered into a joint research agreement with ASKA Pharmaceutical Co., Ltd. to develop novel antibody drugs using PPMX’s proprietary antibody technology. This collaboration aims to create new therapeutics for specific disease areas, although the financial impact on PPMX’s current fiscal year is expected to be minor. The partnership highlights PPMX’s unique screening methods and ASKA’s focus on expanding its drug discovery pipeline to address unmet medical needs.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc., established in 2001, is a biotechnology company based in Tokyo, specializing in drug discovery, antibody research support, and the sale of antibodies and reagents. The company leverages advanced protein expression and antibody production technologies developed at the University of Tokyo to create innovative antibody drugs targeting unmet medical needs, including cancer.
Average Trading Volume: 322,078
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.29B
Find detailed analytics on 4882 stock on TipRanks’ Stock Analysis page.